Theravance Inc: (NASD: THRX)

$39.59

0.05 (0.11%)

Volume 809,813

May 17 04:00 PM ET

Zacks Rank: 3-Hold

 
 
#3
 
 

Overview Quote

Get Overview Quote for:

Stock Activity

Day Low - High 39.02 - 39.73
52wk Low - High 17.06 - 42.41
Previous Close 39.54
Avg. Volume 2,232,346
Industry MED-BIOMED/GENE
Market Cap 3.93 B
Div - Yield 0.00 - 0.00
Beta 1.39
PE (Forward) 0.00
Current Year Est. -1.68
Quarterly Earnings ESP -22.03%

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

3

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Neutral

Zacks Industry Rank

93 out of 265

Equity Research Report

Updated as of 04/29/2013

PREMIUM

( = Change in last 30 days)

Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial

Key Earnings Data

PE (Forward) NA
PEG Ratio NA
Current Year Est. -1.68
Current Quarter Estimate -0.59
Most Accurate Estimate -0.72
Earnings ESP -22.03%
Next Earnings Report Date 08-06-2013
EPS Last Year -1.51
Expected Earnings Growth NA

Company Description

Theravance Inc is focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders.

NYSE data is at least 20 minutes delayed.

NASDAQ data is at least 15 minutes delayed.

Interactive Java Charting | Fundamental Charts

Introducing Zacks Whisper Trader

Turn Earnings Surprises into quick profits.

 

THRX Chart by YCharts

Earnings Estimates

Current Qtr
(06/2013)
Next Qtr
(09/2013)
Current Year
(12/2013)
Next Year
(12/2014)
Average Estimate -0.59 -0.58 -1.68 -1.03
Number of Estimates 3 2 3 4
Low Estimate -0.74 -0.83 -2.22 -1.77
High Estimate -0.34 -0.34 -1.31 NA
Year Ago EPS -0.42 -0.37 -0.20 -1.68
EPS Growth -41.27% -58.11% -741.67% 38.96%

Average Earnings Estimates for THRX

EPS Growth for THRX

Industry Analysis

Name Symbol Previous Close Zacks Rank Zacks Recommendation
THERAVANCE INC THRX 39.54
AETERNA ZENTARS AEZS 2.06
ANIKA THERAPEUT ANIK 14.15
GENTIUM SPA-ADR GENT 8.83
AASTROM BIOSCI ASTM 0.59
ACHILLION PHARM ACHN 7.56
ADDEX THERA LTD ADDXF 6.94
AFFYMAX INC AFFY 1.43
ALEXION PHARMA ALXN 101.82
ALKERMES INC ALKS 30.33

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Financials

EPS TTM -1.51
Sales 136
Net Income -141
Price/Earnings NA
Price/Book 42.54
Price/Cash Flow NA
Price/Sales 393.12

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.